Roche Canada completes negotiations with the pCPA for VABYSMO® to treat wet AMD and DME
May 30th 2023VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.
Read More
Annexon announces topline results from ARCHER Phase 2 trial of ANX007 for geographic atrophy (GA)
May 26th 2023Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.
Read More
Research shows drug could prevent vision loss in premature newborns
May 17th 2023Researchers at the Medical College of Georgia have shown in an animal model of retinopathy of prematurity that the small molecule K604 can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth.
Read More
AI-based eye disease detection startup, Eyetelligence raises $12 million USD from investors
May 17th 2023Eyetelligence will offer non-invasive point-of-care technology to diagnose a range of diseases, including diabetic retinopathy and age-related macular degeneration, with AI algorithmic retinal image analysis.
Read More
Stress resilience-enhancing drugs may provide new therapeutics to treat AMD, DR, and RP
May 11th 2023The study results show the potential of SREDs to treat progressive, chronic retina conditions including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).
Read More
Published data demonstrates the effects of PL8331 in mouse models of retinal disease
April 19th 2023Palatin Technologies, Inc. announced manuscript publication that summarizes data demonstrating the effects of PL8331 in two mouse models of retinal disease, experimental autoimmune uveoretinitis and diabetic retinopathy.
Read More